Pharmacyclics gets boost on 3rd ibrutinib 'breakthrough' designation, new data
This article was originally published in Scrip
Executive Summary
Shares of Pharmacyclics got nearly a 6% bounce on 8 April after the company and its partner Janssen disclosed that the US FDA granted an additional breakthrough therapy designation for ibrutinib as monotherapy to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in patients with deletion of the short arm of chromosome 17.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.